NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

乾眼症症候群(DES):全球藥物預測與市場分析(到2028年)

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2028

出版商 GlobalData 商品編碼 940437
出版日期 內容資訊 英文 145 Pages
訂單完成後即時交付
價格
乾眼症症候群(DES):全球藥物預測與市場分析(到2028年) Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2028
出版日期: 2020年05月30日內容資訊: 英文 145 Pages
簡介

全球乾眼症症候群(DES)市場在2018年∼2028年之間預計將以10.6%的年複合成長率增長,2028年達到111億美元。

本報告提供世界主要9個國家(美國,歐盟五國,日本,中國,印度的)乾眼症症候群(DES)市場的相關調查,提供DES概要及流行病學,市場需求和機會,預測等資訊。

第1章 目錄

  • 表格的清單
  • 圖的清單

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因與病理學
    • 病因
    • 病理生理學
  • 病的分類

第5章 流行病學

  • 病的背景
  • 風險要素與並存症
  • 世界及過去趨勢
  • 預測的調查手法
  • DES的流行病學預測(2018年∼2028年)
  • 討論

第6章 疾病管理

第7章 競爭的評估

第8章 潛在的需求和機會的評估

第9章 管線評估

第10章 現在·今後的企業

第11章 市場展望

第12章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC196PIDR

Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade. However, the current treatment landscape is anticipated to witness a dramatic progress with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM.

Anticipated to be a lucrative market given that its prevalence is expected to increase during the forecast period as well as a significant need to introduce new therapy options for the indication. Therefore, the trend of strategic deals in DES is expected to increase during the forecast period as more late-stage pipeline products are anticipated to enter the market during this period.

New pipeline products will help in addressing clinical unmet needs such as need for more therapies. Environmental unmet needs such as need for better diagnostic tools and appropriate clinical trials design are anticipated to be addressed by a combination of the field progressing in terms of disease understanding and product innovations.

The DES market is expected to witness a CAGR of 10.6% from 2018 to 2028, reaching global value of $11.1 billion.

GlobalData anticipates that 16 pipeline drugs will launch over the forecast period and most dominantly in the US market. A small proportion of these products are based on known MOAs such as cyclosporine-based formulations or corticosteroids, while the other products are based on novel MOAs.

While clinical unmet needs such as need for more treatment options are expected to be met by launch of pipeline products in the forecast period, environmental unmet needs such as those for better diagnostic tools are expected to be addressed by a combination of new product launches and improvement in understanding of the disease pathology.

There is also an anticipation that as more pipeline therapies move into the critical stages of late-stage development and pre-approvals, some of these companies with particularly promising therapy for DES may enter into some form of strategic partnerships with other companies in order to maximize the potential of commercial success of these products.

Key Questions Answered

  • What are the key unmet needs in DES? Will the products in the current pipeline fill these unmet needs?
  • When will the late stage pipeline products launch, and how will it affect drug sales and the overall DES market in the 9MM?

Scope

  • Overview of DES, including epidemiology, pathophysiology, diagnosis, and disease management.
  • Market Data including annualized DES therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in different patient segments (mild, moderate, severe) forecast from 2018 to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DES therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DES therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global DES therapeutics market: Insightful review of the key industry drivers and barriers. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global DES therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DES therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 DES: Executive Summary

  • 2.1 Launch of New Pipeline Products and Increasing Prevalence of DES Are Expected to Drive the DES Market Forward
  • 2.2 Pipeline Products with Distinct MOAs Are Likely to Help Companies to Tackle the DES Market
  • 2.3 New Pipeline Products Will Help in Partially Addressing Some Unmet Needs
  • 2.4 Companies Are Undertaking Strategic Deals in Anticipation of Maximizing Sales of DES Products
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Disease Classification

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
    • 5.4.3 Forecast Assumptions and Methods - Total and Diagnosed Prevalent Cases of DES
    • 5.4.4 Forecast Assumptions and Methods - Total and Diagnosed Prevalent Cases of DES by Severity
  • 5.5 Epidemiological Forecast for DES (2018-2028)
    • 5.5.1 Diagnosed Prevalent Cases of DES
    • 5.5.2 Age-Specific Diagnosed Prevalent Cases of DES
    • 5.5.3 Sex-Specific Diagnosed Prevalent Cases of DES
    • 5.5.4 Diagnosed Prevalent Cases of DES by Severity
    • 5.5.5 Total Prevalent Cases of DES
    • 5.5.6 Total Prevalent Cases of DES by Severity
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of the Analysis
    • 5.6.3 Strengths of the Analysis

6 Disease Management

7 Competitive Assessment

8 Unmet Needs and Opportunity Assessment

9 Pipeline Assessment

10 Current and Future Players

11 Market Outlook

12 Appendix

List of Tables

  • Table 1: DES: Key Metrics in the 9MM
  • Table 2: Risk Factors and Comorbidities for DES
  • Table 3: Diagnostic Tests for DES
  • Table 4: Popular Validated Questionnaires for DES
  • Table 5: Treatment Guidelines for DES
  • Table 6: Country Profile - US
  • Table 7: Country Profile - 5EU
  • Table 8: Country Profile - Japan
  • Table 9: Country Profile - China
  • Table 10: Country Profile - India
  • Table 11: Leading Treatments for DES, 2018
  • Table 12: Comparison of Therapeutic Classes in Development for DES, 2018-2028
  • Table 13: Allergan's DES Portfolio Assessment, 2018
  • Table 14: Aldeyra's DES Portfolio Assessment, 2018
  • Table 15: Aurinia's DES Portfolio Assessment, 2018
  • Table 16: Kala's DES Portfolio Assessment, 2018
  • Table 17: Mitotech's DES Portfolio Assessment, 2018
  • Table 18: Novaliq's DES Portfolio Assessment, 2018
  • Table 19: Novartis' DES Portfolio Assessment, 2018
  • Table 20: Oyster Point Pharma's DES Portfolio Assessment, 2018
  • Table 21: RegeneRX's DES Portfolio Assessment, 2018
  • Table 22: Santen's DES Portfolio Assessment, 2018
  • Table 23: Senju's DES Portfolio Assessment, 2018
  • Table 24: Sun's DES Portfolio Assessment, 2018
  • Table 25: DES Market - Global Drivers and Barriers, 2018-2028
  • Table 26: Key Events Impacting Sales for DES in the US, 2018-2028
  • Table 27: DES Market - Drivers and Barriers in the US, 2018-2028
  • Table 28: Key Events Impacting Sales for DES in the 5EU, 2018-2028
  • Table 29: DES Market - Drivers and Barriers in the 5EU, 2018-2028
  • Table 30: Key Events Impacting Sales for DES in Japan, 2018-2028
  • Table 31: DES Market - Global Drivers and Barriers in Japan, 2018-2028
  • Table 32: Key Events Impacting Sales for DES in China, 2018-2028
  • Table 33: DES Market - Global Drivers and Barriers in China, 2018-2028
  • Table 34: DES Market - Global Drivers and Barriers in India, 2018-2028
  • Table 35: Key Historical and Projected Launch Dates for DES
  • Table 36: Key Historical and Projected Patent Expiry Dates for DES
  • Table 37: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for DES in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in DES During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for DES During the Forecast Period
  • Figure 4: Vicious Circle of DES
  • Figure 5: Classification of DES
  • Figure 6: 9MM, Diagnosed Prevalence of DES, Men and Women, %, Ages ≥18 Years, 2018
  • Figure 7: 9MM, Total Prevalence of DES, Men and Women, %, Ages ≥18 Years, 2018
  • Figure 8: 9MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of DES
  • Figure 9: 9MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of DES
  • Figure 10: 9MM, Sources Used to Forecast the Severity of Diagnosed Prevalent Cases of DES
  • Figure 11: 9MM, Sources Used to Forecast the Severity of Total Prevalent Cases of DES
  • Figure 12: 9MM, Diagnosed Prevalent Cases of DES, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 13: 9MM, Diagnosed Prevalent Cases of DES by Age, N, Both Sexes, 2018
  • Figure 14: 9MM, Diagnosed Prevalent Cases of DES by Sex, N, Ages ≥18 Years, 2018
  • Figure 15: 9MM, Diagnosed Prevalent Cases of DES by Severity, N, Ages ≥18 Years, 2018
  • Figure 16: 9MM, Total Prevalent Cases of DES, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 17: 9MM, Total Prevalent Cases of DES by Severity, N, Ages ≥18 Years, 2018
  • Figure 18: Unmet Needs and Opportunities in DES
  • Figure 19: Products in Clinical Development for DES, 2018
  • Figure 20: Key Phase IIb/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for DES in the 9MM During the Forecast Period
  • Figure 21: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of DES During the Forecast Period
  • Figure 22: Analysis of the Company Portfolio Gap in DES During the Forecast Period
  • Figure 23: Number of Deals in DES Market in the 9MM in Prior Years (2005-2019)
  • Figure 24: Global (9MM) Sales Forecast by Country for DES in 2018 and 2028
  • Figure 25: Sales Forecast by Drug Class for DES in the US, 2018 and 2028
  • Figure 26: Sales Forecast by Class for DES in the 5EU in 2018 and 2028
  • Figure 27: Sales Forecast by Class for DES in Japan in 2018 and 2028
  • Figure 28: Sales Forecast by Class for DES in China in 2018 and 2028
  • Figure 29: Sales Forecast by Class for DES in India in 2018 and 2028